drugset / Trial / NCT02920918

Treatment of Diabetes in Patients With Systolic Heart Failure

NCT02920918

RandomizedParallel-groupTriple-blindTreatment

Summary

Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption \[VO2\]) and ventilator efficiency (minute ventilation \[VE\]/carbon dioxide production \[VCO2\] slope) at cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints). Blood pressure (BP), body water content, body composition, cardiac function, and diet will be also measured (secondary endpoints).

Timeline

Start
2016-10
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg Oral
Comparator Sitagliptin Small molecule 100 mg Oral